Vox Biomedical, Bedford, MA – June 1, 2020. Vox Biomedical has entered into a distribution agreement with Spectratech Inc of Tokyo, Japan. Under the agreement, Vox will offer Spectratech’s cerebral oximetry instrument (OEG series) used for brain mapping in United States and Canada.
Cerebral oximetry maps oxygen supply in the brain for diagnosis of pre-Alzheimer’s disease, Chronic traumatic encephalopathy (CTE), mood swings and concussion. Vox is using Spectratech’s instruments to assess drug intoxication and developing techniques for pain monitoring.
Vox Biomedical, LLC was formed in 2018 to develop a marijuana breathalyzer to determine roadside and workplace intoxication with support from the US Department of Transportation. Vox’s marijuana breathalyzer uses lasers to distinguish THC from CBD in the exhaled breath. A similar instrument to detect opiates in breath is being developed by Vox with the support of National Institutes of Health. Vox is also developing an instrument to detect and identify corona virus (COVID-19) in exhaled breath.
Spectratech, Inc. was established in April of 2001 and is a world leader in neuroimaging, producing brain mapping instruments using infrared light to measure brain oxygenation.
Roger Little, President and CEO of Vox Biomedical said “Spectratech’s brain mapping instruments complement our own development, giving us a range of products to lead Vox Biomedical into our diagnostic market of interest.”
Contact:
Arash Aslani (VP/GM)
Vox Biomedical LLC
info@voxbiomedical.com